Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
7-valent Pneumococcal Conjugate Vaccine · 3 trials · 3 indications
Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study, and as 0.35 ug/ml by the World Health Organization (WHO).
| Arm | Type | Description |
|---|---|---|
| 7vPnC (3-, 4-, 5-, 12-Month) | ACTIVE_COMPARATOR | - |
| 13vPnC (3-, 4-, 5-, 12-Month) | EXPERIMENTAL | - |
| 13vPnC (2-, 4-, 6-, 12-Month) | EXPERIMENTAL | - |
| 13vPnC (3-, 5-, 12-Month) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 7-valent Pneumococcal Conjugate Vaccine | BIOLOGICAL | suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively |
| 13-valent Pnumococcal Conjugate vaccine | BIOLOGICAL | suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively |
| 7-valent pneumococcal conjugate vaccine (vaccine) | BIOLOGICAL | - |
| 23-valent pneumococcal conjugate vaccine (vaccine) | BIOLOGICAL | - |
| Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP) | BIOLOGICAL | - |
Inclusion Criteria: 1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment. 2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator. Exclusion Criteria: 1. Previous vaccination with licensed or investigational pneumococcal vacci...
7-valent Pneumococcal Conjugate Vaccine is used for pneumococcal infection, pneumococcal infections, and HIV infections. It is an investigational vaccine being developed by Pfizer, Inc. (PFE) for the prevention of pneumococcal disease. The vaccine is currently in Phase 3 clinical development.
Pfizer, Inc. (PFE) is developing 7-valent Pneumococcal Conjugate Vaccine. The vaccine is being studied for pneumococcal infections and HIV infections. It is currently in Phase 3 clinical trials, with one completed Phase 3 study involving 1,674 participants.
7-valent Pneumococcal Conjugate Vaccine is in Phase 3 clinical development. It is an investigational vaccine, not yet approved by regulatory authorities. Clinical trials have been completed, including a Phase 3 study in healthy infants in China.
7-valent Pneumococcal Conjugate Vaccine has been studied in clinical trials including NCT00148824, NCT00488826, and NCT01692886. NCT01692886 is a Phase 3 study evaluating the vaccine in healthy infants in China, with 1,674 participants. The trials cover pneumococcal infections and HIV infections.
7-valent Pneumococcal Conjugate Vaccine is not the same as 13-valent Pneumococcal Conjugate Vaccine. They are distinct vaccines with different valencies. A clinical trial, NCT01692886, evaluated both vaccines in healthy infants in China, but they are separate products.